Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) – Drugs In Development, 2024 report and make more profitable business decisions.
Primary myelofibrosis (PMF) is a rare bone marrow disorder marked by irregularities in blood cell production and the development of fibrous tissue within the bone marrow. Hematopoietic stem cells in the bone marrow, responsible for generating red blood cells, white blood cells, and platelets, undergo DNA changes in PMF, leading to continuous abnormal cell reproduction. Over time, these aberrant cells displace healthy cells, disrupting the production of blood cells and causing scarring in the marrow. Symptoms vary, with some individuals remaining asymptomatic initially. However, fatigue, fever, frequent infections, pale skin, night sweats, weight loss, and an enlarged spleen are eventual manifestations. Approximately 50% of patients exhibit a JAK2 gene mutation.
The Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) drugs in development market research report provide comprehensive information on the therapeutics under development for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 21 molecules, with 21 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAntengene Corp Ltd
Bristol-Myers Squibb Co
Cellenkos Inc
Chengdu Jinrui Foundation Biotechnology Co Ltd
Chengdu Zenitar Biomedical Technology Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Disc Medicine Inc
GSK plc
Hangzhou East China Pharmaceutical Group Co Ltd
Imago BioSciences Inc
Incyte Corp
iOnctura SA
Kartos Therapeutics Inc
Karyopharm Therapeutics Inc
MorphoSys AG
Novartis AG
NS Pharma Inc
Sino Biopharmaceutical Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Telios Pharma Inc
Wigen Biomedicine Technology (Shanghai) Co Ltd
Table of Contents
Table
Figures
Frequently asked questions